biotech

We make our case.
Day 2 of the selloff brings in an entirely new kind of buyer.
Give dip buyers the benefit of the doubt on Wednesday.
These names are now undervalued, despite solid results and good fundamentals.
The soft revolution at Softbank under founder Masayoshi Son is transforming a phone company into a private-equity technology giant.
It's a wonder to me how split this market really is.
This corrective action has me feeling optimistic about some new opportunities.
I'm still bothered by the narrowness of the market and some of the weakness under the surface.
The stock is emerging from a one-year base pattern.
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.

Columnist Conversations

Sally Beauty's CEO put his money to work buying 10,000 shares on the new low today (@ $17.91 per share). ...
HD began last Tuesday's session with a huge earnings inspired upside gap. In the early going the stock was up ...
Bloomberg reported recently that there are now more stock market indexes in the US (more than 5,000) than ther...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.